Search Videos and More
News
Dana-Farber Researchers Presented More Than 50 Research Studies at American Association for Cancer Research Annual Meeting 2026
Select presentations by Dana-Farber faculty include a promising clinical trial chemotherapy and RAS inhibitor combination for pancreatic patients, new research on mapping the tumor microbiome using the presence of microorganisms and encouraging results from a clinical trial for older patients with multiple myeloma precursor conditions.
News
Immune Activity Shift a Key Early Step in Breast Cancer Formation
Dana-Farber Cancer Institute research provides the first appreciation of the role of special immunosuppressive regulatory T cells in paving a path for precancerous ductal carcinoma in situ (DCIS) to turn into breast cancer.
News
Dana-Farber Researchers Receive AACR 2026 Scientific Achievement Awards
Dr. Eliezer Van Allen and Dr. Kimberly Stegmaier have been selected by the American Association for Cancer Research (AACR) as recipients of 2026 Scientific Achievement Awards. Both researchers will be honored during the AACR Annual Meeting 2026, held April 17-22 at the San Diego Convention Center.
News
The Next Wave of Immune Cell Therapy
From CAR T to eTCR: New immune cell therapies push beyond blood cancers
News
Dana-Farber Team Develops Open-Access Predictive Tool to Improve Monitoring of Smoldering Multiple Myeloma
The tool, called PANGEA-SMM, outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment. The free online tool can be used immediately to monitor patients.
News
Dana Farber/Boston Children’s Researchers Uncover Distinct Tumor “neighborhoods” with Each Cell Subtype Playing a Specific Role, in Aggressive Childhood Brain Cancer
Their detailed blueprint of tumor cell diversity could guide more precise, targeted treatments for supratentorial ependymomas
News
When Small Cell Lung Cancer Hides from Immune Cells, Blood Vessels May Hold the Key
Researchers at Dana-Farber Cancer Institute have uncovered why small cell lung cancer (SCLC) can stay largely out of reach of the immune system, even when the cancer cells themselves are vulnerable to immune attack.
News
The Gene Fixer
For five decades, Stuart Orkin has harnessed new genetic tools to transform care for blood disorders – helping make sickle cell and beta thalassemia curable.
News
Dana-Farber Research Uncovers Approach to Activating the Immune System Against Metastatic Breast Cancer
Cancer spreads, or metastasizes, when tumor cells shed from a primary solid tumor, for example in the breast, and embed in other organs, such as the lung, liver, and brain, and begin to grow.
News
Researcher Gains Insight into Rare Genetic Diseases
Rare genetic cancers may affect few people, but their complexity makes them powerful windows into how even the most common cancers develop and behave.
News
Dana-Farber, Gustave Roussy to Host Fifth Transatlantic Exchange in Oncology Focused on Cancer Drug Innovation
Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology on Friday, March 27, 2026, bringing together leading cancer researchers and clinicians from the United States and Europe to explore transatlantic innovations in cancer drug research.
News
Making Breakthroughs in ALL From Youth to Adulthood
When Ann Carroll was diagnosed with cancer at age 28, her dream to get married and have a baby felt out of reach. Now, seven years later and cancer-free, she is living that dream with her husband and their 7-month-old son, Teddy.